Merck & Co., Inc.
MRK
Rang in Aktien
#40
Merck & Co., Inc. is a global healthcare leader with operations spanning two... Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Aktienkurs
$145.90
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$359.96B
Veränderung (1 Tag)
0.16%
Veränderung (1 Jahr)
72.07%
Land
US
Handel Merck & Co., Inc. (MRK)
Kategorie
Healthcare
Operative Marge für Merck & Co., Inc. (MRK)
Operative Marge zum October 2026 TTM: 16.65%
Laut den neuesten Finanzberichten und dem Aktienkurs von Merck & Co., Inc. beträgt die aktuelle operative Marge (TTM) 16.65%. Am Ende des Jahres 2024 lag die operative Marge bei 31.51%.
Historie der operativen Marge von Merck & Co., Inc. von 2000 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | 16.65% | -59.58% |
| 2025 | 41.19% | 30.72% |
| 2024 | 31.51% | 541.75% |
| 2023 | 4.91% | -84.08% |
| 2022 | 30.84% | 13.80% |
| 2021 | 27.10% | 102.84% |
| 2020 | 13.36% | -34.06% |
| 2019 | 20.26% | -4.07% |
| 2018 | 21.12% | 24.68% |
| 2017 | 16.94% | 22.66% |
| 2016 | 13.81% | -27.73% |
| 2015 | 19.11% | 20.80% |
| 2014 | 15.82% | -9.13% |
| 2013 | 17.41% | -16.70% |
| 2012 | 20.90% | 11.88% |
| 2011 | 18.68% | 155.89% |
| 2010 | 7.30% | -50.20% |
| 2009 | 14.66% | -42.53% |
| 2008 | 25.51% | 9.86% |
| 2007 | 23.22% | 42.54% |
| 2006 | 16.29% | -38.81% |
| 2005 | 26.62% | -9.52% |
| 2004 | 29.42% | -22.80% |
| 2003 | 38.11% | -10.08% |
| 2002 | 42.38% | -3.18% |
| 2001 | 43.77% | 94.36% |
| 2000 | 22.52% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 49.72% | -97.01% |
US
|
|
| 25.70% | -98.46% |
US
|
|
| 29.32% | -98.24% |
US
|
|
| 26.59% | -98.40% |
CH
|
|
| 31.24% | -98.12% |
CH
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.